Stock of The Day: After Today’s Big Decline, Is Tenax Therapeutics Inc’s Near-Term Analysis Negative?

Stock of The Day: After Today's Big Decline, Is Tenax Therapeutics Inc's Near Term Analysis Negative?

The stock of Tenax Therapeutics Inc (NASDAQ:TENX) is a huge mover today! About 1.08 million shares traded hands or 2621.91% up from the average. Tenax Therapeutics Inc (NASDAQ:TENX) has risen 7.17% since March 2, 2016 and is uptrending. It has underperformed by 1.08% the S&P500.
The move comes after 6 months negative chart setup for the $62.39M company. It was reported on Oct, 5 by Barchart.com. We have $1.83 PT which if reached, will make NASDAQ:TENX worth $8.73 million less.

Analysts await Tenax Therapeutics Inc (NASDAQ:TENX) to report earnings on January, 2. After $-0.17 actual EPS reported by Tenax Therapeutics Inc for the previous quarter, Wall Street now forecasts 0.00% EPS growth.

According to Zacks Investment Research, “Tenax Therapeutics, Inc. is a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market. The Company specializes in creating pharmaceuticals and medical devices in the fields of oxygen therapeutics, blood substitutes, and liquid ventilation and implanted glucose sensing. Tenax Therapeutics Inc., formerly known as Oxygen Biotherapeutics, Inc., is based in United States.”

More notable recent Tenax Therapeutics Inc (NASDAQ:TENX) news were published by: Businesswire.com which released: “Tenax Therapeutics Provides Clinical Update for Lead Candidate Levosimendan” on October 05, 2016, also Businesswire.com with their article: “Oxygen Biotherapeutics Announces Name Change to Tenax Therapeutics (NASDAQ: TENX)” published on September 16, 2014, Businesswire.com published: “Tenax Therapeutics Announces Second Quarter 2016 Financial Results and …” on August 11, 2016. More interesting news about Tenax Therapeutics Inc (NASDAQ:TENX) were released by: Businesswire.com and their article: “Tenax Therapeutics Provides Update of Phase 3 LEVO-CTS Trial for LCOS” published on February 01, 2016 as well as Seekingalpha.com‘s news article titled: “Tenax Therapeutics: Evaluating Levosimendan In Septic Shock” with publication date: October 13, 2015.

TENX Company Profile

Tenax Therapeutics Inc, formerly Oxygen Biotherapeutics, Inc., incorporated on April 17, 2008, is a specialty pharmaceutical firm focused on developing and commercializing a portfolio of products for the critical care patients. The Company’s principal business is to acquire, or discover, develop, and commercialize novel therapeutic products for disease indications that represent significant areas of clinical need and commercial opportunity. The Company’s lead product is levosimendan, a calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The Firm is also developing Oxycyte, a systemic perfluorocarbon, or PFC, product, which is oxygen carrier for use in situations of acute ischemia. In addition, it also has developed a family of perfluorocarbon oxygen carriers for use in personal care, topical wound healing, and other topical indications. Life Newco, Inc. is the wholly owned subsidiary of the Company.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment